

## WHE UNITED STATES PATENT AND TRADEMARK OFFICE

## CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

(only for Continuation or Divisional applications under 37 CFR 1.53(d))

Docket No.: 176/60197 (6-11405-675/676)

Express Mail No.: E1989354428UŚ Examiner: Larry R. Helms, Ph.D.

Art Unit: 1642

Commissioner for Patents Washington, D.C. 20231 **BOX: CPA** 

This is a Request for filing a:

[X] continuation or [] divisional application

plication. (CPA) of prior application number

under 37 CFR 1.53(d), continued prosecution application, (CPA) of prior application number 09/016,743, filed on January 30, 1998, of Joseph D. Rosenblatt, Pia Challita-Eid, Sherie L. Morrison, Camille N. Abboud, Seung-Uon Shin entitled CHIMERIC ANTIBODY FUSION PROTEINS FOR THE RECRUITMENT AND STIMULATION OF AN ANTITUMOR IMMUNE RESPONSE.

The above-identified prior pending application is hereby expressly abandoned as of the filing date of this request for a continued prosecution application (CPA).

1.	[]	Enter the unentered amendment previously filed on [*enter date] under 37 CFR 1.116 in the prior nonprovisional application.						
2.	[X]	A preliminary amendment is enclosed.						
3.	[]	application is filed by fewer than all the inventors named in the prior ication, 37 CFR 1.53 (d)(4).						
	a.	[ ] Delete the following inventor(s) named in the prior nonprovisional application:						
-	b.	[ ] The inventor(s) to be deleted are set forth on a separate sheet enclosed herewith.						
4.	ъ. []							

6. The filing fee is calculated on the basis of the claims existing in the prior application as amended above:

07/24/2002 AWONDAF1 00000129 09016743

01 FC:231

370.00 OP

	(Col. 1)	(Col. 2)		SMALL ENTITY			LARGE ENTITY		
FOR:	NO. FILED	NO. EXTRA		RATE	FEE	<u>OR</u>	RATE	FEE	
BASIC FEE	xxxxxxxx	xxxxxxx		XXXXX	\$370	<u>OR</u>	xxxxx	\$740	
TOTAL CLAIMS	10 - 20 =	0		x 9=	\$	<u>OR</u>	x 18 =	\$	
INDEP CLAIMS	1 - 3 =	0		x 42 =	\$	<u>OR</u>	x 84 =	\$	
[ ] MULTIPLE DEPENDENT CLAIM PRESENTED				x140 =	\$	<u>OR</u>	x280 =	\$	
*If the Total Claims are less than 3, ente		TOTAL	\$370	<u>OR</u>	TÓTAL	\$			

- 7. [X] A check in the amount of \$370.00 is enclosed to cover the above filing fee.
- 8. [X] The Commissioner is hereby authorized to charge fees which may be required, or credit overpayment to Deposit Account No. 14-1138. A duplicate copy of this sheet is enclosed.
- 9. Small entity status:
  - [X] Applicants claim small entity status. (See 37 CFR 1.27.)
  - [ ] A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
  - [ ] is no longer claimed.
- 10. [X] A copy of the Request for Four-Month Extension of Time in prior application.
- 11. [X] Declaration Of Seung-Uon Shin Under 37 C.F.R. § 1.132 (4 pages) with Appendix A-E.
- 12. [X] A self-addressed, prepaid postcard for acknowledging receipt.
- 13. Other:

Address all future communications to (may only be completed by Applicant, or attorney or agent of record):

Michael L. Goldman NIXON PEABODY LLP Clinton Square P.O. Box 31051 Rochester, New York 14603-1051

Respectfully submitted,

Date: July 19, 2002

Michael L. Goldman Registration No. 30,727

NIXON PEABODY LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603 Telephone: (585) 263-1304 Facsimile: (585) 263-1600

R601711.1

PATENT Docket No.: 176/60197 (6-11405-675/676)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Rosenblatt et al.

Serial No.

CPA of 09/016,743

Cnfrm. No.

7389

Filed

Herewith

For

CHIMERIC ANTIBODY FUSION

PROTEINS FOR THE RECRUITMENT

AND STIMULATION OF AN

ANTITUMOR IMMUNE RESPONSE

Examiner:

Larry R. Helms. Ph.D.

Art Unit: 1642

KO

7-27-02

## PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202

Box: CPA

Dear Sir:

In response to the final rejection, please amend the above-identified application as follows:

In the Claims:

Please cancel claims 11-24 and 26-/16 without prejudice. Please amend claim 1 as follows:

1. (Thrice Amended) A chimeric molecule suitable for stimulating a tumor specific immune response comprising:

a complete antibody having heavy and light chains each with an N terminus and being capable of specifically binding to a tumor cell associated antigen, and

a chemokine, which is coupled to the N terminus of the heavy or light chain of the antibody such that the antibody remains capable of binding to the tumor cell associated antigen and the chemokine retains activity.

and I